Nektar Therapeutics (NASDAQ:NKTR) shares have slid down over the previous month, which may be worrying some investors. After a recent check, the stock has been down -17.45% for the month. Taking a wider glance, shares are -5.70% since the start of the year. With increased market volatility, shareholders may be having to choose whether to dump the shares or hang on for a possible rebound.
Equity analysts may still see some upside to the stock despite the recent downward trend. Sell-side firms, on a consensus basis have a 1.40 recommendation, according to First Call on Nektar Therapeutics (NASDAQ:NKTR). The recommendation is based on a 1 to 5 scale where 1 or 2 indicates a Buy recommendation, 3 a Hold and 4-5 a Sell.
In taking a look at technical levels, shares are trading -11.01% away from the 50 day simple moving average and 5.27% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -20.47% away from it’s 52- week high and 60.18% away from its 52 week low. After the recent decrease, investors may also look to see if the stock has entered oversold territory and could possibly ripe for a bounceback. Traditionally a stock is considered to be oversold when the Relative Strength Index moves below 30. As of writing, Nektar Therapeutics’s RSI stands at 33.38. In looking at volatility levels, the shares saw weekly volatility of 3.43% and 4.15% over the past month.
Disclaimer: This article is in no way encouraging or advising whether to buy or sell the security, Being a successful investor during one time period does not mean that you will make money when you actually invest during a later time period. Market conditions constantly change. When investing in securities or options you may lose all of the money you invested. Stock trading and investing involves risk of loss to investment capital and past performance is not a guarantee of future results.